TNF Pharmaceuticals (NASDAQ:TNFA) Shares Down 10.3% – Here’s Why

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) fell 10.3% during trading on Thursday . The stock traded as low as $3.55 and last traded at $3.75. 783,960 shares traded hands during trading, a decline of 78% from the average session volume of 3,511,287 shares. The stock had previously closed at $4.18.

Analyst Upgrades and Downgrades

Several research firms have commented on TNFA. Wall Street Zen upgraded shares of TNF Pharmaceuticals to a “sell” rating in a report on Friday, September 5th. Weiss Ratings reiterated a “sell (e)” rating on shares of TNF Pharmaceuticals in a report on Saturday, September 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

TNF Pharmaceuticals Trading Down 10.3%

The firm has a market cap of $6.93 million, a price-to-earnings ratio of -0.02 and a beta of 2.04. The firm’s fifty day moving average price is $5.13 and its 200-day moving average price is $12.43.

TNF Pharmaceuticals (NASDAQ:TNFA) last announced its earnings results on Tuesday, August 19th. The company reported ($18.00) earnings per share (EPS) for the quarter.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.